A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Icahn School of Medicine at Mount Sinai, New York

UPMC- Hillman Cancer Center, Pittsburgh

Cancer Center at Greater Baltimore Medical, Baltimore

Virginia Cancer Care Specialist, PC, Fairfax

University of South Carolina, Charleston

Sarah Cannon Research Institute - SCRI, Nashville

Henry-Joyce Cancer Center, Nashville

Norton Cancer Institute, Louisville

University of Michigan Comprehensive Cancer Center, Ann Arbor

Washington University, St Louis

Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha

University of Oklahoma, Oklahoma City

Mary Crowley Cancer Research Center, Dallas

South Texas Accelerated Research Therapeutics, San Antonio

Comprehensive Cancer Centers of Nevada, Las Vegas

University of Washington-Seattle Cancer Care Alliance, Seattle

Yale Center for Clinical Investigation, New Haven

Site CA15002, Edmonton

Site CA15004, Montreal

Site IT39008, Milan

Site IT39006, Modena

Site JP81002, Chiba

Site JP81001, Tokyo

Site PT35104, Porto

Site KR82001, Seoul

Site KR82002, Seoul

Site KR82003, Seoul

Site KR82004, Seoul

Site KR82005, Seoul

Site KR82006, Seoul

Site KR82007, Seoul

Site ES34002, Barcelona

Site ES34006, Barcelona

Site ES34010, Barcelona

Site ES34014, Barcelona

Site ES34003, Cataluna

Site ES34004, Cataluna

Site ES34007, Madrid

Site ES34012, Madrid

Site TW88601, Taipei

Site TW88602, Taipei

Site GB44006, Manchester